Virbac : Q3 2024 sales: no better than expected / no momentum effect
>Q3: +7.7% and +3.4% l-f-l (vs +15.2% and +11.3% l-f-l in H1) - Virbac’s Q3 sales totalled € 339m, i.e. +7.7% (+3.4% l-f-l vs our forecast of +5%e). Globion and Sasaeah contributed 6.5 points. At 9M, sales stand at € 1,042.1m (+12.6%) with pet sales at +11.9% and livestock sales at +3.2%. Virbac confirmed its guidance of sales growth of 7-9%, a +5.5% scope effect (at real scope, between +12.5% and +14.5%) and an EBIT ratio around 16% of sales.A ...Virbac is an independent veterinary pharmaceutical laboratory. Co. develops and provides veterinarians and farmers with medicines and vaccines that improve the health of food producing animals. Co. markets a range of products designed for pets and livestock. It offers seven types of products for companion animals (Parasiticides, Immunology, Antibiotics/dermatology, Specialties, Equine, Specialized pet food and Other products), and four types of products for food producing animals (Bovine parasiticides, Bovine products (excluding parasiticides), Pig/poultry antibiotics and Other products). Co. markets its products in the ethical (veterinarian) and OTC markets.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.